Interventional trials represent 45.9% of study design sales and phase 3 trials account for 40.2% within the phase segment in 2026. The non-alcoholic steatohepatitis clinical trials market is estimated at USD 3.2 billion in 2026 and is forecast to post a 7.0% CAGR between 2026 and 2036.